Cargando…

Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease

Detalles Bibliográficos
Autores principales:	Liendo-Martínez, Katiuska Herminia, Baratech-Calpena, Francisco Javier, Ji, Zichen, Pedraza-Serrano, Fernando, Caballero-Segura, Francisco José, de Miguel-Díez, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568410/ https://www.ncbi.nlm.nih.gov/pubmed/37842287 http://dx.doi.org/10.1016/j.opresp.2023.100268

Ejemplares similares

Antifibrotic in interstitial lung diseases: When, where, and how long?
por: Rai, Deependra K., et al.
Publicado: (2022)

Enfermedad de Erdheim-Chester: dificultades en el diagnóstico y tratamiento
por: Fuentes Alonso, Marta, et al.
Publicado: (2021)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
por: Wilfong, Erin M., et al.
Publicado: (2021)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
por: Shumar, John N., et al.
Publicado: (2021)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases
por: Dsouza, Kevin G., et al.
Publicado: (2023)

A family history of Hermansky–Pudlak syndrome complicated with pulmonary fibrosis: a case series and review
por: Liendo Martinez, Katiuska, et al.
Publicado: (2021)

Characteristics and outcomes of patients hospitalized with interstitial lung diseases in Spain, 2014 to 2015
por: Pedraza-Serrano, Fernando, et al.
Publicado: (2019)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2019)

Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study
por: Martínez-Besteiro, Elisa, et al.
Publicado: (2023)

Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis
por: Taweesedt, Pahnwat, et al.
Publicado: (2023)

A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities
por: Dhooria, Sahajal, et al.
Publicado: (2022)

Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites
por: Miguel-Carrasco, José Luis, et al.
Publicado: (2017)

Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?
por: Zhu, Michael Z L, et al.
Publicado: (2021)

Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review
por: Bos, Saskia, et al.
Publicado: (2021)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
por: Erre, Gian Luca, et al.
Publicado: (2021)

Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
por: Sugino, Keishi, et al.
Publicado: (2021)

Use of antifibrotic drugs in familial interstitial pneumonia: analysis of one family
por: Estrella, Deborah dos Reis, et al.
Publicado: (2021)

The effect of anesthetic preconditioning with sevoflurane on intracellular signal-transduction pathways and apoptosis, in a lung autotransplant experimental model()
por: Garutti, Ignacio, et al.
Publicado: (2018)

Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects
por: Nawa, Hideki, et al.
Publicado: (2022)

Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group
por: Salvi, Sundeep Santosh, et al.
Publicado: (2022)

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
por: Chaudhary, Sachin, et al.
Publicado: (2020)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

RNA Sequencing Uncovers Antifibrotic Genes during Lung Fibrosis Resolution
por: Han, Hongwei, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs
por: Guilherme, Rafael F., et al.
Publicado: (2023)

Lung transplantation for interstitial lung disease: evolution over three decades
por: Leong, Swee W, et al.
Publicado: (2023)

Phosphatidylethanolamine Induces an Antifibrotic Phenotype in Normal Human Lung Fibroblasts and Ameliorates Bleomycin-Induced Lung Fibrosis in Mice
por: Vazquez-de-Lara, Luis G., et al.
Publicado: (2018)

Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
por: Kashihara, Tairo, et al.
Publicado: (2020)

Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group
Publicado: (2022)

Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
por: Chaudhary, Sachin, et al.
Publicado: (2021)

Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity
por: Takahashi, Hiroshi, et al.
Publicado: (2021)

Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
por: Seifirad, Soroush, et al.
Publicado: (2021)

[Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia
por: Sellarés, Jacobo, et al.
Publicado: (2022)

Antifibrotics in India
por: Dhar, Raja
Publicado: (2019)

HGF Expressing Stem Cells in Usual Interstitial Pneumonia Originate from the Bone Marrow and Are Antifibrotic
por: Gazdhar, Amiq, et al.
Publicado: (2013)

Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents
por: Itano, Junko, et al.
Publicado: (2020)

In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway
por: Hsieh, Yi-Hsien, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1v5t2e8m1hpgf4bnc9b8hnp7n